SEC Comment Letter 0000000000-22-014001 to Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc.
Date: Dec. 29, 2022 · CIK: 0001857044 · Accession: 0000000000-22-014001
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269000
Letter
United States securities and exchange commission logo December 29, 2022 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Re:Indaptus Therapeutics, Inc. Registration Statement on Form S-1 Filed December 23, 2022 File No. 333-269000 Dear Jeffrey Meckler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary M. Emmanuel, Esq.
Show Raw Text
United States securities and exchange commission logo
December 29, 2022
Jeffrey Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 23, 2022
File No. 333-269000
Dear Jeffrey Meckler:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Gary M. Emmanuel, Esq.